SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: puborectalis who wrote (597)3/26/1998 9:16:00 PM
From: Wilfredo Pagani  Read Replies (2) of 965
 
It had been presented to FDA for aproval since dec 1997. It had already passed the 3 phases of research require by FDA.The studies shows that there is improvement after first infussion but this is a chronic illness and the infussion had to be repeated after some weeks. My concern is that to find the right dosage and timing for treatment it will take sometime and most prescription must be of large centers probably on research protocols for more time than expected. WPagani
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News